Title
Formulacija i fizičko-hemijska karakterizacija liofilizovanih i radioobeleženih imunokonjugata trastuzumaba
Creator
Arev, Marija S., 1984
CONOR:
79066121
Copyright date
2021
Object Links
Select license
Autorstvo-Nekomercijalno-Bez prerade 3.0 Srbija (CC BY-NC-ND 3.0)
License description
Dozvoljavate samo preuzimanje i distribuciju dela, ako/dok se pravilno naznačava ime autora, bez ikakvih promena dela i bez prava komercijalnog korišćenja dela. Ova licenca je najstroža CC licenca. Osnovni opis Licence: http://creativecommons.org/licenses/by-nc-nd/3.0/rs/deed.sr_LATN. Sadržaj ugovora u celini: http://creativecommons.org/licenses/by-nc-nd/3.0/rs/legalcode.sr-Latn
Language
Serbian
Cobiss-ID
Theses Type
Doktorska disertacija
description
Datum odbrane: 03.12.2021.
Other responsibilities
predsednik komisije
Marković, Bojan
član komisije
Živković, Jelena
član komisije
Vranješ-Đurić, Sanja
član komisije
Vlajković, Marina
Academic Expertise
Medicinske nauke
University
Univerzitet u Nišu
Faculty
Medicinski fakultet
Group
Katedra za farmakologiju sa toksikologijom
Alternative title
Formulation and physicochemical characterization of freeze-dried and radiolabeled trastuzumab immunoconjugates
Publisher
[М. S. Аrev]
Format
156 listova
description
Bibliografija: listovi 139-155,
Biografija autora: list 156.
description
Pharmaceutical chemistry
Abstract (en)
Monoclonal antibody-based therapy is one of the most successful therapeutic approaches for solid tumors and other malignancies. Radiolabeling of antibodies with radioisotopes provides development of selective and specific radiopharmaceuticals with better radiotherapeutical effect. Trastuzumab is a monoclonal antibody used for the treatment of HER2-positive breast cancer. The radioimmunoconjugate formulation of trastuzumab offers a strategy that is promising for selective and specific cancer therapies therefore it was chosen for development of new formulation of radioimunoconjugate for the therapy. Trastuzumab has been conjugated with three chelators, p-SCN-Bn-DTPA, p-SCN-Bn-1B4M-DTPA, p-SCN-Bn-DOTA using different molar ratios (1:10, 1:20, 1:50). The conjugates were labeled with non-radioactive metal ions Y3+ and Lu3+ and used to determine the possible physicochemical changes in the structure after radioactive metal introduction. Immunoconjugates (1:20 ratio) were characterized by HPLC-UV. They show the high levels of integrity, without degradation products present in comparison with the native antibody. The retained secondary structure of the antibody was proven by spectroscopic analysis with FT‐IR and Raman spectroscopy. Characteristic amide I band at ~1670 cm-1 and amide III band (1230‐1300 cm-1), specific for antibody principally composed of β‐sheets, were detected in Raman spectra. FT-IR spectra also contain the amide I (1700‐1600 cm-1), amide II (1480‐1575 cm-1) and amide III bands (1255‐1244 cm-1) specific for secondary structure of the IgG1 proteins. The sufficient number of chelator molecules bound to a single antibody was an important step to ensure stable binding to radioactive isotopes with a high radiolabeling
yield. For this characterization, we used MALDI-TOF MS, which method proved successful conjugation and identification of a sufficient number of chelators per antibody molecule. Antibody integrity, purity and possible aggregate formation after lyophilization and non-radioactive isotope labeling we determined using SDS-PAGE. The obtained gels shows that there is no destruction of immunoconjugates in all samples, regardless of their concentration and relationship with ligands. Radiolabeling of freeze-dried formulation with 90Y and 177Lu (with a specific activity of 200 μCi / mL) has been shown successful binding with high radiolabeling yield (>96% for 90Y and >99% for 177Lu). Stability studies using ITLC-SG method high stability of radioimmunoconjugate 72 h after labelling with non-ssignificant radioisotope release (<25% for 90Y and <5% for 177Lu).
The results of this work confirm the possibility of further testing of radioimmunoconjugates based on trastuzumab in the direction of in vivo pharmacokinetic studies in animal models, with the aim of determining the most appropriate formulation suitable for clinical trials.
Authors Key words
trastuzumab, p-SCN-Bn-DTPA, p-SCN-Bn-1B4M-DTPA,
p-SCN-Bn-DOTA, 177Lu, 90Y
Authors Key words
Trastuzumab, p-SCN-Bn-DTPA, p-SCN-Bn-1B4M-DTPA,
p-SCN-Bn-DOTA, 177Lu, 90Y
Classification
616-097-073:544.2(043.3)
Subject
B 740 Pharmacological sciences, pharmacognosy, pharmacy, toxicology
Type
Tekst
Abstract (en)
Monoclonal antibody-based therapy is one of the most successful therapeutic approaches for solid tumors and other malignancies. Radiolabeling of antibodies with radioisotopes provides development of selective and specific radiopharmaceuticals with better radiotherapeutical effect. Trastuzumab is a monoclonal antibody used for the treatment of HER2-positive breast cancer. The radioimmunoconjugate formulation of trastuzumab offers a strategy that is promising for selective and specific cancer therapies therefore it was chosen for development of new formulation of radioimunoconjugate for the therapy. Trastuzumab has been conjugated with three chelators, p-SCN-Bn-DTPA, p-SCN-Bn-1B4M-DTPA, p-SCN-Bn-DOTA using different molar ratios (1:10, 1:20, 1:50). The conjugates were labeled with non-radioactive metal ions Y3+ and Lu3+ and used to determine the possible physicochemical changes in the structure after radioactive metal introduction. Immunoconjugates (1:20 ratio) were characterized by HPLC-UV. They show the high levels of integrity, without degradation products present in comparison with the native antibody. The retained secondary structure of the antibody was proven by spectroscopic analysis with FT‐IR and Raman spectroscopy. Characteristic amide I band at ~1670 cm-1 and amide III band (1230‐1300 cm-1), specific for antibody principally composed of β‐sheets, were detected in Raman spectra. FT-IR spectra also contain the amide I (1700‐1600 cm-1), amide II (1480‐1575 cm-1) and amide III bands (1255‐1244 cm-1) specific for secondary structure of the IgG1 proteins. The sufficient number of chelator molecules bound to a single antibody was an important step to ensure stable binding to radioactive isotopes with a high radiolabeling
yield. For this characterization, we used MALDI-TOF MS, which method proved successful conjugation and identification of a sufficient number of chelators per antibody molecule. Antibody integrity, purity and possible aggregate formation after lyophilization and non-radioactive isotope labeling we determined using SDS-PAGE. The obtained gels shows that there is no destruction of immunoconjugates in all samples, regardless of their concentration and relationship with ligands. Radiolabeling of freeze-dried formulation with 90Y and 177Lu (with a specific activity of 200 μCi / mL) has been shown successful binding with high radiolabeling yield (>96% for 90Y and >99% for 177Lu). Stability studies using ITLC-SG method high stability of radioimmunoconjugate 72 h after labelling with non-ssignificant radioisotope release (<25% for 90Y and <5% for 177Lu).
The results of this work confirm the possibility of further testing of radioimmunoconjugates based on trastuzumab in the direction of in vivo pharmacokinetic studies in animal models, with the aim of determining the most appropriate formulation suitable for clinical trials.
“Data exchange” service offers individual users metadata transfer in several different formats. Citation formats are offered for transfers in texts as for the transfer into internet pages. Citation formats include permanent links that guarantee access to cited sources. For use are commonly structured metadata schemes : Dublin Core xml and ETUB-MS xml, local adaptation of international ETD-MS scheme intended for use in academic documents.